Bromocriptine

	WikiDoc Resources for Bromocriptine
Articles
Most recent articles on Bromocriptine Most cited articles on Bromocriptine Review articles on Bromocriptine Articles on Bromocriptine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bromocriptine Images of Bromocriptine Photos of Bromocriptine Podcasts & MP3s on Bromocriptine Videos on Bromocriptine
Evidence Based Medicine
Cochrane Collaboration on Bromocriptine Bandolier on Bromocriptine TRIP on Bromocriptine
Clinical Trials
Ongoing Trials on Bromocriptine at Clinical Trials.gov Trial results on Bromocriptine Clinical Trials on Bromocriptine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bromocriptine NICE Guidance on Bromocriptine NHS PRODIGY Guidance FDA on Bromocriptine CDC on Bromocriptine
Books
Books on Bromocriptine
News
Bromocriptine in the news Be alerted to news on Bromocriptine News trends on Bromocriptine
Commentary
Blogs on Bromocriptine
Definitions
Definitions of Bromocriptine
Patient Resources / Community
Patient resources on Bromocriptine Discussion groups on Bromocriptine Patient Handouts on Bromocriptine Directions to Hospitals Treating Bromocriptine Risk calculators and risk factors for Bromocriptine
Healthcare Provider Resources
Symptoms of Bromocriptine Causes & Risk Factors for Bromocriptine Diagnostic studies for Bromocriptine Treatment of Bromocriptine
Continuing Medical Education (CME)
CME Programs on Bromocriptine
International
Bromocriptine en Espanol Bromocriptine en Francais
Business
Bromocriptine in the Marketplace Patents on Bromocriptine
Experimental / Informatics
List of terms related to Bromocriptine

Bromocriptine
Clinical data
Pregnancy; category	A;
Routes of; administration	oral
ATC code	G02CB01 (WHO) N04BC01 (WHO);
Legal status
Legal status	?;
Pharmacokinetic data
Bioavailability	28% of oral dose absorbed
Metabolism	?
Elimination half-life	12-14 hours
Excretion	85% bile (faeces)
Identifiers
	IUPAC name Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2 -methylpropyl)-;
CAS Number	25614-03-3;
PubChem CID	31101;
DrugBank	APRD00622;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C32H40BrN5O5
Molar mass	654.595

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bromocriptine (brand names include Parlodel), an ergoline derivative, is a dopamine agonist that is used in the treatment of pituitary tumors and Parkinson's disease.

Uses

Amenorrhea, female infertility, galactorrhea, hypogonadism, and acromegaly may all be caused by pituitary problems, such as hyperprolactinaemia, and therefore, these problems may be treated by this drug.

It has also used in some countries to prevent lactation following childbirth if the mother does not wish to breastfeed; one of dopamine's effects on the pituitary is as an antagonist of prolactin production by lactotrophs. However, the FDA removed this indication in 1995, because of concerns with respect to an increased risk of heart attack, seizure and stroke.

Because of prolactin's role in stimulating proliferation of the T-lymphocytes of the immune system, bromocriptine has also been used to suppress the immune system in organ transplant patients.^[1]

Since bromocryptine acts as a dopamine agonist, it has potential use in treating cocaine addiction, since the addictive effects of cocaine are caused by it blocking dopamine reuptake. Although it has negligible subjective effects when administered alone, studies show it has the potential to significantly ease the cocaine withdrawal syndrome.^[2]^[3]

There appear to be some connections between insulin insensitivity and dopamine. A company called Veroscience ^[4] is using bromocriptine to treat diabetes and obesity, and their website postulates a connection between neurotransmitters and seasonal variation in insulin sensitivity among vetebrate animals.^[5] There are also some connections between temperature and dopamine and serotonin production.^[6] In addition, new research indicates that patients with diabetes are more likely to develop parkinson's disease, which is characterized by a dopamine deficiency in the brain.

Structure

Like all ergopeptides, bromocriptine is a cyclol; two peptide groups of its tripeptide moiety (shown in black at the upper left of the Figure) are crosslinked, forming the >N-C(OH)< juncture between the two lactam rings.

References

↑ Clodi M, Kotzmann H, Riedl M, Schmidt A, Barnas U, Muhlbacher F, Mustafa G, Horl WH, Waldhausl W, Mayer G, Luger A., 1997. The long-acting dopamine agonist bromocriptine mesylate as additive immunosuppressive drug after kidney transplantation. Nephrol Dial Transplant. 1997 Apr;12(4):748-52.
↑ Campbell A, Baldessarini RJ, Cremens C, Teicher MH, Marsh E, Kula NS, 1989. Bromocriptine antagonizes behavioral effects of cocaine in the rat. Neuropsychopharmacology 1989 Sep; 2(3):209-24.
↑ KL Preston, JT Sullivan, EC Strain and GE Bigelow, 1992. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther. 1992 Jul;262(1):279-91.
↑ http://www.veroscience.com/research.html
↑ Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999 Oct;8(10):1683-1707.
↑ http://sulcus.berkeley.edu/mcb/165_001/papers/manuscripts/_281.html

Template:Ergolines Template:Dopamine agonists

de:Bromocriptin hu:Bromokriptin it:Bromocriptina sv:Bromokriptin

[1] Clodi M, Kotzmann H, Riedl M, Schmidt A, Barnas U, Muhlbacher F, Mustafa G, Horl WH, Waldhausl W, Mayer G, Luger A., 1997. The long-acting dopamine agonist bromocriptine mesylate as additive immunosuppressive drug after kidney transplantation. Nephrol Dial Transplant. 1997 Apr;12(4):748-52.

[2] Campbell A, Baldessarini RJ, Cremens C, Teicher MH, Marsh E, Kula NS, 1989. Bromocriptine antagonizes behavioral effects of cocaine in the rat. Neuropsychopharmacology 1989 Sep; 2(3):209-24.

[3] KL Preston, JT Sullivan, EC Strain and GE Bigelow, 1992. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther. 1992 Jul;262(1):279-91.

[4] ttp://www.veroscience.com/research.html

[5] Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999 Oct;8(10):1683-1707.

[6] ttp://sulcus.berkeley.edu/mcb/165_001/papers/manuscripts/_281.html

[1]

[2]

[3]

[4]

[5]

[6]

Bromocriptine

Contents

Overview

Uses

Structure

See also

References

Navigation menu

Clinical data
Pregnancy category	A
Routes of administration	oral
ATC code	G02CB01 (WHO) N04BC01 (WHO)
Legal status
Legal status	?
Pharmacokinetic data
Bioavailability	28% of oral dose absorbed
Metabolism	?
Elimination half-life	12-14 hours
Excretion	85% bile (faeces)
Identifiers
IUPAC name Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2 -methylpropyl)-
CAS Number	25614-03-3
PubChem CID	31101
DrugBank	APRD00622
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₃₂H₄₀BrN₅O₅
Molar mass	654.595